 ROCKVILLE, Md.--BUSINESS WIRE--GlycoMimetics, Inc. Nasdaq: GLYC today announced that new post hoc analyses of the Phase 3 RESET study evaluating the efficacy of rivipansel, its wholly-owned product candidate, in VOC show that pediatric patients treated with rivipansel within approximately 30 hours of the onset of acute crisis pain experienced statistically significant improvements in the primary efficacy endpoint of time to readiness for discharge TTRFD compared to placebo as well as in t 